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I. Literature Review 
I. Disease Burden of neglected tropical diseases or NTD’s 
The burden of neglected tropical diseases or NTDs is greater than that of malaria, tuberculosis, 
and other diseases such as HIV/AIDS (Hotez 2011) .One billion of the 2.7 billion poorest people 
living on less than $2 US dollars a day are infected by one or more neglected tropical diseases, 
which intensify poverty and stigmatize those that are affected (Liese, Rosenberg et al. 2010). 
NTDs which often overlap geographically, predominantly affect poor populations living in rural 
tropical and subtropical regions. According to the WHO 2010 report on NTDs, “100% of low-
income countries are affected by at least five neglected tropical diseases simultaneously”(WHO 
2010). NTDs contribute not only to a high morbidity and disability, but also contribute to an 
ongoing cycle of poverty and shame for the people they affect (Hotez 2011).  
 
According to a 2002 report by the World Health Organization (WHO), neglected tropical 
diseases, which include soil transmitted helminths (STH), trachoma, schistosomiasis, 
onchoceraisis, and lymphatic filariasis (LF), contribute to 5% of the global burden of infectious 
diseases (Smits 2009). The world’s highest prevalent NTDs which include hookworm, ascaris, 
trichuris, lymphatic filariasis, schistosomiasis, trachoma and onchocerciasis infect over 1 billion 
people globally and contribute to 52.1 million disability-adjusted life years (DALYs) (Fenwick 
2012). The burden of disease caused by NTDs may be under estimated due to the fact that they 
may be chronic or that the proper diagnostic tools or epidemiology to estimate the true burden of 
disease are lacking (Smits 2009). The chronic disease caused by the NTDs can result in 
disfigurement, impaired child development, poor pregnancy outcomes, and reduced productivity 
(Hotez, Molyneux et al. 2007).  
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In 2010, the World Health Organization published its first report on neglected tropical 
diseases which stated that the highest prevalence NTDs could be eliminated by 2020 (WHO 
2010) .  Strategies to battle NTDS include increased hygiene, environmental improvement, 
vector control, sustained socio economic development, and preventive chemotherapy(Smits 
2009). Preventive chemotherapy through targeted mass drug administration is one of the most 
“tool ready” and cost-effective methods for controlling NTDs. The donation of drugs or 
availability of drugs at very low costs from pharmaceutical companies has made the mass drug 
administration for control of NTDs possible, even in resource poor countries. According to the 
WHO 2012 report on the roadmap for reducing the impact of global NTDs,  short term solutions 
such as preventative chemotherapy can significantly reduce morbidity and transmission (WHO 
2012). However, long term elimination will not be possible without access to clean water, 
sanitation, and improved living conditions (WHO 2012).  The WHO and United States Agency 
for International Development or USAID have established elimination and control goals for 
NTDs targeted by mass drug administration or MDAs. LF is targeted for elimination by 2020. 
Onchocerciais is targeted for elimination in the Americas by 2016. In addition, the WHO would 
like to reduce the prevalence of NTDs by 50% in 70% of the population living in areas endemic 
for these diseases (Hotez 2011).  
 
II. Overview of the major NTDs  
A. Trachoma 
Trachoma is the leading infectious cause of blindness worldwide (Burton 2007). Trachoma is 
caused by the bacterium Chlamydia trachomatis and can cause visual impairment and blindness 
(Hu, Harding-Esch et al. 2010). Trachoma infection has been observed for centuries in all areas 
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of the world including Europe and North America, but today it is found predominantly in poor 
countries in sub-Saharan Africa and Asia (Hu, Harding-Esch et al. 2010). Trachoma is estimated 
to cause 2.3-4.0  million DALYs (Smits 2009). Trachoma is transmitted by flies. Repeated 
infection of the ocular surface initiates chronic inflammatory responses that lead to cornea 
damage and scarring(Feasey, Wansbrough-Jones et al. 2010). As the scar tissue shortens, the eye 
lids are distorted and it causes the eyelashes to come into contact with the surface of the eye 
(trichiasis). When trichiasis occurs the cornea is compromised and blindness occurs(Burton 
2007).  
MDA for trachoma is a 20mg/kg dose of azithromycin. Other methods of controlling trachoma 
include improved sanitation, facial hygiene, and health education. One way to undo the effects of 
the blindness caused by trachoma is through eyelid surgery which reverses the in-turning of the 
eyelashes and may also improve non-visual symptoms (Mathew, Turner et al. 2009). Through 
the WHO established Alliance for the Global Elimination of Blinding Trachoma, trachoma 
control is implemented through the SAFE Strategy (WEST 2003). The components of the SAFE 
strategy include both short term and long term interventions for control and prevention of 
trachoma and trichiasis: S, surgery for trichiasis, A, antibiotics to prevent infection, F, facial 
cleanliness, and E, environmental improvement. The WHO has targeted the elimination of 
blinding trachoma for the year 2020. Treatment for trachoma is a single oral dose of the 
antibiotic azithromyxin with treatment every 6-12 months (Mathew, Turner et al. 2009). 
B. Soil Transmitted Helminths (STH) 
Soil transmitted helminthiasis (STH) is caused primarily by the nematodes Ascaris lumbricoides 
(roundworm), Ancylostoma duodenale, Necator americanus (hookworm), and Trichuris 
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trichiura (whipworm) which infect the intestine (Bethony, Brooker et al. 2006).  Poor personal 
hygiene and sanitation contribute to the transmission of STH (Bethony, Brooker et al. 2006). 
Global prevalence of ascariasis, hookworm, and trichriasis is 600 million(Smits 2009). It is 
estimated that the burden of STH ranges from 4.7-39 million DALYS (Smits 2009). STH are 
transmitted through contaminated soil or consuming fruits and vegetables that haven’t been fully 
cooked, washed or peeled. After the worms are acquired through ingestion or the soil, they infect 
the gastro-intestinal tract, reproduce, and release eggs into the environment through the 
feces(Feasey, Wansbrough-Jones et al. 2010). Children infected from STH can suffer from 
anemia, vitamin A deficiency, impaired growth, malnutrition, and reduced cognitive 
development (WHO 2010). The main approach to achieve control or elimination of the highly 
prevalent STH’s includes MDA with albendazole or mebendazole together with 
ivermectin(Hotez 2011).  
C. Schistosomiasis 
Schistosomisasis or bilharziasis is caused by the trematodes,  Schistosoma haematobium, 
Schistosoma mansoni, Schistosoma japonica, and Schistosoma mekongi(WHO 2010). 
Schistosomiasis is common in places with poor sanitation and is acquired by swimming, bathing 
or coming into contact with contaminated fresh water (Steinmann, Keiser et al. 2006). Fresh 
water snails carry the larval form (schistosomes) of the trematodes which can penetrate human 
skin (Feasey, Wansbrough-Jones et al. 2010). The disease burden of schistosomiasis is estimated 
to be 1.8-4.5 million DALYs (Smits 2009). It is estimated that nearly 600 million people suffer 
from schistosomiasis with 90% in Africa (Hotez 2011). In Africa, having schistosomasis has 
been reported to increase the likelihood of contracting HIV/AIDS and nearly 300,000 people die 
of schistosomiasis each year(Hotez and Fenwick 2009). The symptoms of schistosomiasis are 
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not caused by the worms themselves, but by the body’s reaction to the eggs as they pass through 
blood vessels, intestine, ureters, bladder or become lodged in the liver or lungs(Feasey, 
Wansbrough-Jones et al. 2010).  The eggs can cause chronic ill health and can damage major 
organs including the liver, intestine, spleen, lungs, and bladder (Ross, Bartley et al. 2002). 
School aged children are most at risk for schistosomiasis. Children who are repeatedly infected 
by shistosomes can develop anemia, malnutrition, and impaired cognitive development which 
can affect school attendance(WHO 2010). Schistosomiasis treatment and elimination strategies 
include treatment with Praziquantel based on body weight or  height as well as improved access 
to clean water and sanitation (Smits 2009).                                                                                   
D. Onchoceriasis 
Onchoceriasis more commonly known as river blindness, is caused by the nematode worm 
Onchocerca volvus (Duke 1990).  The WHO estimates that 37 million people are infected with 
O. volvulus worldwide; of these people 270,000 are blind and 500,000 have some sort of visual 
impairment. Onchoceriasis causes nearly 1 million DALYs (Boatin and Richards Jr 2006). 
Transmission of onchoceriasis occurs from multiple bites from the Simuliaum black fly which 
breeds near fast running streams and rivers. People most at risk for onchocerciasis include 
fishermen, farmers, or those that spend long hours or live near the black fly breeding sites. In 
fact, in areas near rivers where the disease exists almost every person in a community may be 
infected and almost half of the population will suffer from blindness (Etya'al 2001). Symptoms 
of the disease do not manifest until one to three years after the parasite has been injected into its 
victim (Etya'al 2001). The adult worm lives in the fibrous and subcutaneious nodules. The adult 
females produce millions microfilariae which migrate under the skin and to the eyes(Crompton 
and WHO 2006). 
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Since 1987 onchocerciasis control has relied on the donation of ivermectin (Mectizan
®
, Merck & 
Co., Inc.) through the Mectizan Donation Programme (MDP).(Boatin and Richards Jr 2006). 
Unfortunately ivermectin does not kill the adult but only the larvae, so treatment must be 
continued for the life of the adult worm which can be as long as 15 years (Amazigo, Leak et al. 
2012). International programs including ,the African Program for Onchocerciasis control  
(APOC) , the Onchocerciasis Control Programme of West Africa, and the Onchocerciasis 
Elimination Program for the Americas have been successful with implementation of larvicide 
spraying for black fly control and mass drug administration of ivermectin (Richards, Boatin et al. 
2001). Interruption of Transmission of Oncocerciasis has been documented in endemic areas of 
Guatemala, and several regions in Mali and Senegal (Feasey, Wansbrough-Jones et al. 2010).  
E. Lymphatic filariasis (LF) 
Lymphatic filariasis also known as elephantiasis is a parasitic infection caused by Wuchereria 
bancrofti, Brugia malai, and Brugia timori. LF has no animal reservoir and is transmitted by 
mosquitoes. The main symptoms of LF include swelling of the limbs or lymphodema, 
elephantiasis, and swelling of genital organs or hydrocele (Richards, Eigege et al. 2011). LF is 
estimated to have a disease burden 5.6-5.8 DALYS per million people. It is estimated that 1.2 
billion people live in areas endemic for LF(Crompton and WHO 2006). Three drugs are 
recommended for the treatment of LF, ivermectin, diethlcarbamazine (DEC), and albendazole. 
Adult worms are not totally eliminated by one drug treatment, so a combination of drugs is 
required. The strategy to eliminate lymphatic filariasis has two components with one component 
being MDA of DEC+ albendazole or ivermectin+ albendazole. The other component involves 
home-based care and community based programs to guide individuals suffering from the disease 
and educate persons on hygiene and treatment of affected limbs (Crompton and WHO 2006).  In 
20 
 
order to reduce transmission of LF, it is recommended to have a coverage of 70-80% over a 
period of 5-6 years (Ottesen, Hooper et al. 2008).    In the year 2000, the WHO established the 
Global Program to Eliminate Lymphatic Filariais (GPELF). Through MDA, 1.9 billion 
treatments to people in 48 countries have been delivered. Between 2000-2008, the GPELF has 
prevented more than 6 million cases of hydrocele ,4 million cases of lymphodema, and 6 million 
DALYs have been averted(Ottesen, Hooper et al. 2008). 
III. Preventive chemotherapy as a strategy to control or eliminate NTDs. 
According to the WHO, nearly 90% of NTDs can be treated with drugs that only need to be 
administered once or twice each year in contrast to diseases like AIDS, and TB (WHO 2012). 
Large scale chemotherapy is a cost-effective intervention that contributes to several Millennium 
Development goals outlined by the United Nations including, eradicating poverty and hunger, 
achieving universal primary education, promoting gender equality, reducing childhood mortality,  
improving maternal health, and  fighting HIV/AIDS, TB, and malaria(Crompton and WHO 
2006). Preventative chemotherapy (PCT) is “the regular, large-scale elimination of drugs—either 
alone or in combination—to entire population groups living in areas where helminth infections 
and trachoma are prevalent, with the aim of reducing their morbidity and 
transmission”(Montresor, Gabrielli et al. 2012). The WHO recommends preventative 
chemotherapy as a strategy for the control of highly prevalent NTDs including lymphatic 
filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, and 
trachoma(Crompton and WHO 2006).  Preventative chemotherapy can be targeted based on the 
epidemiology of a disease in a particular area or can be applied to an entire population in an 
endemic area using mass drug administration or MDA (Crompton and WHO 2006).  Treatment 
and frequency of the MDA depends on endemicity of a disease in a particular area. Integrated 
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preventative chemotherapy is a new, key strategy for battling areas where more than one NTD is 
endemic.  Coordinated implementation of preventative chemotherapy for LF, onchocerciasis, 
schistosomiasis, STH, and trachoma helps to attain higher coverage rates and to efficiently use 
resources(Montresor, Gabrielli et al. 2012).  
Large scale preventative chemotherapy is made possible by the donation or availability of drugs 
at low cost by pharmaceutical companies. Albendazole is donated by GlaxoSmithKline. 
Ivermectin (Mectizan®) and praziquantel are donated by Merck. Albendazole and ivermectin are 
available as long as necessary until the elimination program reaches success. Mebendazole is 
donated by Johnson and Johnson. Azithromycin (Zithromax ®) used to treat Trachoma, is 
donated by Pfizer. In order to assess the performance of large scale chemotherapy it is important 
to determine the coverage of the MDA. Coverage refers to the proportion of the persons in the 
target population who took the recommended drugs (Crompton and WHO 2006). Determining 
coverage is critical to assess the effectiveness of the MDA (Smits 2009).   Low coverage 
threatens the success of MDA programs and may present a risk for the development of drug 
resistance(Smits 2009).  Health education and community participation are critical for achieving 
high coverage rates and  the success of the MDA programs (Smits 2009).  
IV. Current PCT and MDA programs 
Progress has been made in the last 10 years to scale up NTD control and public health 
partnerships between governments, NGOs, and pharmaceutical companies, (Montresor, Gabrielli 
et al. 2012). It is estimated that over 700 million individuals are being treated for one or more 
NTDs each year(Montresor, Gabrielli et al. 2012).  A summary of MDA programs, 
pharmaceutical partners, and number of people treated are listed in table 1. After many 
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successful rounds of preventative chemotherapy onchoceriasis is on track for elimination in the 
Americas. For exam ample in Guatemala researchers have observed the disruption of 
onchocerciasis transmission and children between 6-12 years of age living in endemic areas had 
no serological evidence of infection(Cruz-Ortiz, Gonzalez et al. 2012).  In 2011, Columbia 
became the first country in the Americas to successfully eliminated onchocerciasis and is on 
track for elimination in Brazil, Colombia, Ecuador, Guatemala, Mexico and Venezuela 
(Gustavsen, Hopkins et al. 2011). Globally, progress has been made in the last 10 years to scale 
up NTD control through public health partnerships between governments, non-governmental 
organizations (NGOs), and pharmaceutical companies.  It is estimated that over 700 million 
people are being treated for one or more NTDs each year (WHO 2010). For instance an 
estimated 22 million people have been protected from LF infection and disease saving an 
estimated $24.2 billion US dollars (Addiss and Filariasis 2010).  
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Table 1: Summary of programs for NTDs Adapted from Montressor et al. 2012 and Smitts 2009, 
Fenwick 2012 
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V. History of Preventative Chemotherapy in Cameroon 
The health system in Cameroon is organized into central, regional and  into 179 smaller local 
health districts (Tchuem Tchuenté, Kamwa Ngassam et al. 2012). The population density in 
Cameroon varies greatly from region to region and can range from 7.4 inhabitants/km
2
 to 141.5 
inhabitants/km
2
(Tchuem Tchuenté, Kamwa Ngassam et al. 2012). 
Cameroon has a high prevalence onchocerciasis, lymphatic filariasis, schistosomiasis, trachoma 
and soil transmitted helminiths and affect millions of people throughout the country(Klopp 
2009).  According to Helen Keller International, a partner working with the Cameroon Ministry 
of Health , over10 million people are at risk for onchocerciasis, 5 million are at risk for 
schistosomiasis, and 2 million people may already be infected with schistosomiasis (Klopp 
2009).  In south west Cameroon, the prevalence of STH infections ranged from 30-40% 
depending on if person lives in an urban or rural area (Mbuh, Ntonifor et al. 2012).  
In Cameroon, the National Strategic Plan for the control of STH and schistosomiasis began in 
2004 with a limited budget and under a small scale(Tchuem Tchuenté, Kamwa Ngassam et al. 
2012). In 2007, with the help of international and national partners including the Cameroon 
Ministry of Health, Helen Keller International, United States Agency for International 
Development, Children Without Worms, Mectizan® Donation program, and African Program 
for Onocerciasis Control and other partners, the program was implemented all over the country. 
De-worming campaigns targeting school aged children have occurred annually since 
2007(Tchuem Tchuenté, Kamwa Ngassam et al. 2012). In 2009, the Government of Cameroon 
implemented an integrated approach for controlling NTDs for greater efficiency and cost-
effectiveness(Tchuente and N'Goran 2009). With monetary support from the United States 
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Agency for International Development (USAID), the Cameroon government coordinates co-
administration of several drugs for control of  NTDs including lymphatic filariasis, 
onchoceriasis, trachoma, schistosomiasis and soil transmitted helminths(Tchuem Tchuenté, 
Kamwa Ngassam et al. 2012). 
One item to be concerned about while implementing PCT in Cameroon is the occurrence of Lao 
Lao, a filarial nematode, in areas also endemic for LF, onchoccerciasis, schistosomiasis, and 
STH.  When persons have high levels of loiasis, Ivemectin treatment can result in severe adverse 
reactions events which could include encephalopathy(Crompton and WHO 2006).  
Recent mapping campaigns to determine the prevalence of STH and schistosomiasis have 
demonstrated that the prevalence of STH and schistosomiasis has declined from 81.1-93% down 
to 10.5%-46%, proving the impact of annual deworming and NTD control campaigns(Tchuem 
Tchuenté, Kamwa Ngassam et al. 2012).   
VI. Purpose of the Study 
In order to accurately measure the achievement of mass drug administration programs and drug 
delivery it is important to make sure that the drugs reach everyone that needs them and that the 
coverage is high enough to interrupt transmission. It is believed that through adequate 
chemotherapy to an at risk population will reduce the prevalence of infection and lead to 
elimination (Worrell and Mathieu 2012).  MDA programs rely mostly on reported drug coverage 
calculated based on the number of doses given during the drug distribution and the denominator 
is the targeted population(Worrell and Mathieu 2012). Another way to measure drug coverage is 
through coverage surveys administered to households in the area where the MDA was 
administered. Coverage surveys are important for validating the reported coverage and in 
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addition, provide valuable information including basic demographics of the targeted population 
and reasons for non-compliance (Worrell and Mathieu 2012).  The WHO recommends 
monitoring MDA programs through coverage surveys, however, coverage surveys require both 
monetary and human resources that may be scarce in resource poor settings (Worrell and 
Mathieu 2012).  Validating the reported coverage through a coverage survey is an important 
component of MDA program evaluation and monitoring(Worrell and Mathieu 2012). 
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Abstract: 
 
Health education and preventive chemotherapy are main strategies to control or eliminate 
neglected tropical diseases (NTDs) such as lymphatic filariasis (LF), trachoma, onchocerciasis, 
schistosomiasis (SCH), and soil-transmitted helminthiasis (STH).   Integrated MDA for LF, 
onchocerciasis, SCH, STH, and trachoma were organized in the Koza district of Cameroon from 
July to August 2011.  Ivermectin (IVM) and albendazole (ALB) were distributed for LF to the 
entire population except pregnant or lactating women, children <90 cm in height, and the 
severely ill.  Azithromycin was distributed at least one week after the LF MDA to all persons 
older than 6 months of age.  Praziquantel (PZQ), targeting school age children (SAC), was only 
distributed in schools. In order to validate reported coverage and assess the knowledge and 
attitude of the population towards NTDs and MDAs, an independent coverage and Knowledge, 
Attitudes, and Practice (KAP) survey was administered.   The WHO recommended population 
based 30-cluster coverage survey was implemented. Clusters were selected by Probability 
Proportional to Estimated Size and in each cluster, 10 houses were selected using the improved 
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expanded program on immunization random walk. Coverage questions were administered by 
trained interviewers to each person living in selected houses and KAP questions were asked to a 
randomly selected adult in the house.  
A total of 1303 persons participated in the coverage survey and 149 adults answered the KAP 
questions. The survey coverage estimates for IVM /ALB and azithromycin are 76.9% (95% CI 
72.0-81.9), 86.8% (95% CI 80.9-92.7), respectively, while the reported coverage is 80.3% and 
93%, respectively. The survey coverage estimated for PZQ among SAC is 39.9% (95% CI 30.7-
49.1), reported coverage is unknown.  There was no significant association between participation 
in the MDA and age, gender, or knowing the disease. SAC who attended school were 269 times 
as likely to have taken PZQ and 3 times as likely to have taken LF drugs as SAC not attending 
school.  Less than 50% of respondents had heard of LF and only 31.8% could mention at least 
one LF symptom. More than 70% of respondents had heard of STH, SCH, and trachoma, but 
only 52.3%, 40%, 30%, respectively, knew at least one way to prevent or treat STH, SCH, and 
trachoma. Despite low or incorrect knowledge of LF, SCH, STH, and trachoma, overall, MDA 
coverage was good except for the PZQ which was only distributed in school.   
Keywords: Mass Drug Administration, Neglected Tropical Diseases, Cameroon, Coverage, 
Survey 
 
Introduction: 
The burden of neglected tropical diseases or NTDs is greater than that of malaria, tuberculosis, 
and other diseases such as HIV/AIDS(Hotez 2011) . The world’s highest prevalent NTDs which 
include hookworm, ascaris, trichuris, Lymphatic filariasis, schistosomiasis, trachoma and 
onchocerciasis infect over 1 billion people globally and contribute to 52.1 million disability-
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adjusted life years (DALYs) annually (Fenwick 2012). The chronic disease caused by the NTDs 
can result in disfigurement, impaired child development, poor pregnancy outcomes, and reduced 
productivity (Hotez, Molyneux et al. 2007). Preventive chemotherapy through targeted mass 
drug administration is one of the most “tool ready” and cost-effective methods for controlling 
NTDs. The donation of drugs or availability of drugs at very low costs from pharmaceutical 
companies has made the mass drug administration for control of NTDs possible, even in resource 
poor countries.  
In Cameroon, the plan for control of STH and schistosomiasis began in 2004 with a limited 
budget and under a small scale. In 2007, with the help of international and national partners, the 
program was implemented all over the country. De-worming campaigns targeting school aged 
children have occurred annually since 2007 (Tchuem Tchuenté, Kamwa Ngassam et al. 2012). 
An integrated approach for controlling the most prevalent NTDs including not only STH and 
schistosomiasis but LF, trachoma, and onchoceraisis was established in 2009 for greater 
efficiency and cost-effectiveness (Tchuente and N'Goran 2009). In July-August 2011, a mass 
drug administration (MDA) campaign was implemented in the Koza District of Cameroon, in the 
extreme nord region.   In order to validate reported coverage and assess the knowledge and 
attitude of the population towards NTDs and MDAs, an independent coverage and Knowledge, 
Attitudes, and Practice (KAP) survey was administered.  
 
Methods 
Mass drug administration for LF, onchocerciasis, schistosomiasis, STH and trachoma were 
organized in the Koza district in July-August 2011.  The Centers for Disease Control and 
Prevention (CDC) and the Cameroon Ministry of Health implemented the standard WHO 
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cluster-survey protocol  in 8 of the 14 sub-districts of Koza District: Koza 1 and 2, Gaboua, 
Ouval, Gouzda Wayam, Djingliya, M’tsikar, Ndougui Kilda .  
MDA program consisted of a sub-district based distribution of single dose of 400 mg Ivermectin,  
single dose 400 mg Albendazole, 20mg/kg azithromyxin. Praziquantel doses of 40mg/kg were 
delivered in an annual primary school-based distribution. 
Ivermectin and albendazole were distributed to the entire population except pregnant women, 
lactating women in the first week after birth, children <90 cm in height, and the severely ill.  
Azithromycin was distributed at least one week after the distribution of ivermectin and 
albendazole to all persons above the age of 6 months.  Praziquantal was only distributed in 
schools to school aged children (SAC).   
After the MDA, the districts were required to report coverage of each ivermectin/albendazole , 
Azithromycin, and praziquantel  to the Ministry of Health. Reported coverage for the Koza 
district for ivermectin/ albendazole and azithromycin was 80.3% and 93% respectively. Reported 
coverage for praziquantel was not available.2.2 Survey sampling methodology 
The sampling methodology was a population based 30- cluster survey as recommended by the 
WHO LF manual and described in detail by Worrell and Mathieu (Worrell and Mathieu 2012). 
Clusters were selected by Probability Proportional to Estimated Size (PPES) and in each cluster, 
10 houses were selected using the improved EPI walk(Worrell and Mathieu 2012). The first step 
was a census of all members living in the selected household including age, gender, and whether 
or not they participated in the MDA. If the one or more of the persons in the household were not 
present, the parents or other family member served as a proxy.  One random member of the each 
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household over the age of 14 was chosen to take the KAP survey. No alternates were selected if 
the person was not present at the time of the survey 
2.3 Questionnaires 
A MDA coverage and knowledge attitudes, and practices (KAP) survey were administered in 
each household selected via the sampling procedure discussed above. Survey questions were 
open ended, but included answers that the authors anticipated would be most mentioned. For 
most questions, multiple answers were possible. The questionnaires were administered in French. 
Informed consent forms were included with each questionnaire.  The coverage questionnaire 
questions included demographics including age and gender, and if they were answering for 
themselves or for a family member. The coverage questionnaire also included questions on 
participation in the MDA and which type of medication the person received. For children ages 5-
14, they were also asked if they attended school and whether or not they received the medication 
at school. The KAP survey gathered information on the participant’s knowledge of the NTD 
treatment, and prevention,  participation in the MDA, and reasons for non-compliance.   For the 
KAP survey, questions were included to assess knowledge, attitudes and practices regarding 
control of LF, STH, schistosomiasis, and trachoma infections. Further questions included 
knowledge of someone in the household of village with signs or symptoms of LF, trachoma, or 
schistosomiasis.  Additionally adults answered questions regarding access to sanitation and 
improved drinking water sources.  
2.6 Interview training 
The interviewers were district-level health personnel selected by the Ministry of Health. The 
interviewers were not involved in the MDA distribution. The Ministry of Health (MoH) and 
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CDC organized a two -day training which included sampling methodology, informed consent 
and administering the questionnaire. The training included in class lectures, a role-play exercise 
and a one-day practical session.   
2.7 Data management and analysis 
Data was entered into Epi Info database by a staff member from the MoH in the district 
personnel. Data were analyzed using SAS, version 9.2. Treatment coverage was calculated as x/n 
where x is the number of persons treated and n is the total amount of persons surveyed. Various 
age strata were created based on age (0-13, 14-24, 25-39, 40-59, and greater than 59 years), 
gender, and school attendance. Categorical data were compared using the Mantel Haenszel Chi 
square test.   KAP MDA coverage was calculated as x/n where x is the number of persons treated 
and n is the total amount of persons who participated in the KAP survey.   
Demographics were calculated using frequencies. For the KAP survey, participation in the MDA 
and relationship to gender and age were calculated and tested using Mantel Haenszel Chi square 
tests.  
2.8 Ethical considerations 
The protocol was evaluated by a CDC human subjects review board and was determined to be 
exempt from IRB approval because it consisted of a program evaluation. Verbal informed 
consent was obtained from participants over 18 years of age. If the person was less than 18 years 
old, verbal informed consent was asked from the head of the household or responsible adult. If 
the individual was 6-18 years old, a verbal assent was asked of the child in addition to consent by 
the representing adult.  
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Results 
3.2 Household survey 
3.2.1 Demographics 
 There were 1303 respondents for the coverage survey in the Koza district (Table 1). The 
median age was 15 years (range 0-110 years) and 52% were female (Table 1).  Almost one fifth 
were under 5 years old (N=221, 17%). One third of the persons were school age (N=428, 32.9%, 
5-14 years).  
3.2.2 Treatment coverage  
 Coverage was defined as having received ivermectin/albendazole , Azithromycin, or 
praziquantel during the MDA.  Survey coverage for ivermectin/albendazole was 76.9% (CI 72-
81.9), Azithromycin 86.8% (CI 80.9-92.7). Praziquantel coverage for children 5-14 years was 
39.9% (CI 30.7-49.1).  There was no significant difference between male and female coverage 
for any of the drugs. There was a statistically significant difference for coverage between self-
reporting and reporting for others for ivermectin/albendazole OR 2.2 (95% CI 1.6-3.0) and 
praziquantel OR 4.2 (95% CI 2.6-6.7) but not for azithromycin OR 0.977 (95% CI 0.69-1.38) 
(Figure 1).  For those self-reporting, the coverage was 85.6% for Ivermectin/Albendazole, 52% 
for Praziquantel, and 86% for Azithromycin(Figure 1).  The coverage when someone else was 
reporting was 73% for Ivermectin/Albendazole, 20% for Praziquantel, and 84% for 
Azithromycin (Figure 1).  
3.2.3 Treatment coverage and school attendance 
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Praziquantel was only distributed in schools.  Children ages 5-14 years old were 269 times more 
likely to have taken Praziquantel than children not attending school (p <0.05) Table 2. Of those 
that attended school, 21% of parents reporting for their children did not know if they had taken 
praziquantel.  There was a statistically significant association between drug coverage and 
attending school for ivermectin/albendazole and Praqiquantel administered during the June 2011 
MDA (Table 2). Coverage for Azithromycin was not statistically associated with school 
attendance Cochran mantel haenszel test statistic (p =0.06) 
 3.3 Knowledge, Attitudes, and Practices (KAP) survey 
3.3.1 Demographics 
For the KAP survey, 149 individuals were surveyed and 35.8% (N=53) were male (Table 1). The 
median age of the respondents was 41 years (range 14-100) (Table1). 3.3.2 Treatment coverage 
according to the KAP survey. 
Of the adults participating in the KAP survey, 87.2% (95% CI 78.8%-95.5%) reported taking the 
each medication during the MDA.  Of those who participated in the MDA, 64% (95% CI: 55%-
73%) were female  
3.3.3 Lymphatic filariasis (LF) knowledge 
Of those participating in the KAP survey, 44.3% (66/149) of the participants had heard about LF. 
Among people who had heard about LF, 32% (21/66) knew at least one symptom (lymphedema 
or swelling) (Table 3).  A common incorrect symptom mentioned was itching not related to LF 
(9%, 6/66) and 21% (14 /66) said they did not know any symptoms of LF.   Among people who 
had heard about LF, only  4.5% (3/66) knew that it is transmitted by mosquitoes and  34.5% did 
37 
 
not know how it was transmitted and gave an incorrect responses . For example, 9% of those that 
heard of LF incorrectly believed that LF is transmitted through food and/or water . One fourth of 
the  respondents knew that taking medicine could prevent LF  while nearly one third believed 
traditional treatment could prevent LF (Table 3).  
3.3.4 Soil transmitted helminths (STH) knowledge 
Eighty five percent of individuals surveyed had heard of STH but only 52.3% (78/126) reported 
that STH can be prevented with medication and fewer than  5.4% knew that good hygiene and 
clean food preparation could prevent STH (Table 3).  
3.3.5 Schistosomiasis knowledge 
Nearly 75% of those surveyed had knowledge of schistosomiasis (Table 3). There was a 
significant relationship between gender and having heard of schistosomiasis.  Males had 2.7 
higher odds of hearing about schistosomiasis compared to females 95%CI (1.06-6.6). Of 
individuals who had heard of schistosomiasis 38% (42/109) knew how to treat or prevent 
schistosomiasis and 27% (30/109) gave the wrong answer. For example 5% (6/109) thought that 
avoiding the sun was a way to prevent or treat schistosomiasis.  
3.3.6 Trachoma knowledge 
Nearly 70% of individuals surveyed heard of trachoma (Table 3). Of individuals who had heard 
of trachoma less than 35% (33/98) knew how to treat or prevent trachoma and 30% (29/98) 
replied that traditional treatment was the way to prevent or treat trachoma (Table 3).  
For all the neglected tropical diseases targeted by the MDA there was not a significant 
relationship between knowledge of the disease and participation in the MDA. 
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3.3.7 Knowledge of persons with symptoms 
A summary of respondent’s answers about knowing someone in their household or village with 
symptoms of trachoma or lympatic filariais is presented in Table 4. Of the 149 respondents, 11-
12% reported knowing someone with bloody urine and blindness in their households. Trachoma 
was the most common disease observed in the village followed by lymphatic filariasis. 
Individuals who reported that someone in their household or village had symptoms were not 
statistically more likely to have taken the participated in the MDA than individuals who did not 
have someone in their household or village with symptoms. 
3.3.8 Participation in the mass drug administration according to the KAP questionnaire 
Eighty seven percent (129/149) of adult selected for the KAP survey respondents reported that 
they had taken all the medication during the MDA campaign. The most common reason cited for 
not taking the medication was being out of town at the time of distribution. The second most 
common answer was being pregnant or breastfeeding.  Of those taking the medicine, 17.2% 
(22/149) reported that they experienced side effects. Stomach ache and nausea were the most 
common side effects reported (36.5%), followed by dizziness (18.2%), itching (18.2%), and 
diarrhea (9%).   
3.3.9 Water and sanitation 
The source of drinking water for the majority of respondents was 36% river (N=54) and rain 
water collection 34%(N=50). Over 25% of respondents used water from a spring (N=40), 9% tap 
water (N=14), and 4% bought water (N=6). The majority of the survey population used latrines 
as their main form of sanitation 89.2% (N=133).  A minority of respondents practiced open 
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defecation in the field, river, or a hole in the ground, 7%, 2%, and 1% respectively. There was no 
relationship between source of water or sanitation and participation in the MDA. 
4. Discussion 
MDA guidelines require participant countries to collect and report data concerning the number of 
persons treated during MDAs. However, census figures are often inaccurate, making it difficult 
to calculate correct coverage rates. In addition reported coverage figures may also be an 
overestimation or underestimation of actual coverage. In the Koza district the reported coverage 
rates were comparable to coverage survey rates.  According to the KAP survey, the coverage for 
the MDA was 87%, well above the target 80% threshold established by WHO.  Achieving 
consistent high levels of coverage greater than 75% is essential for interrupting transmission of 
lymphatic filariasis, STH, schistosomiasis, and trachoma. Obtaining accurate data on treatment 
coverage is very important for program evaluation.  Although the coverage for the Koza district 
MDA may be incomplete or inaccurate to evaluate the health impact, evidence from other studies 
have demonstrated that MDA is beneficial and reduces parasite morbidity in the targeted 
populations (Amazigo, Leak et al. 2012).  
Ivermectin/Albendazole and Azithromycin were both above the targeted coverage of 75%. 
However, the survey coverage for Praziquantel was lower than expected.  The coverage for 
Praziquantel, which was only distributed in schools, was much higher for self-reporting than 
when one someone else answered. This seems to indicate that the parents were not aware that 
Praziquantel was distributed in schools. Although the school based approach has been reported to 
be successful for the distribution of drugs in other similar settings it ultimately depends on how 
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many children attend school. Children who do not attend school will be left out of the MDA if 
this is the only way school age children are targeted. 
The coverage survey had several limitations. First, these survey results are based on self-reported 
data and may be subject to recall bias.   However, studies in Togo reported that 80% of 
respondents were able to accurately recall participation in MDA up to one year after the 
campaign ended (Worrell and Mathieu 2012). Second, given that parents often served as proxies 
for their children and were not present during the actual treatment, the information provided by 
the parents may be less reliable than if the information was provided by the children themselves. 
In order to maintain successful high treatment coverage it is important to examine the predictors 
of non-compliance with treatment.  According to the coverage survey, there was no difference in 
coverage between males and females or between age groups. For Praziquantel, one significant 
predictor of compliance was school attendance. Although the coverage survey did not determine 
any predictors of compliance for Ivermectin/Albendazole and Azithromycin (azithromycin), the 
coverage was still over 70% for the population living in the Koza district.  
The KAP survey did not reveal any significant predictors of compliance with the MDA.   In the 
Koza district, the knowledge of the diseases targeted for the MDA was very poor. In the Koza 
district most participants in the KAP survey did not have knowledge about the diseases or the 
purpose of the MDA including etiology, prevention, treatment, transmission, and personal risk.  
Even those that had knowledge of the disease were not more likely to have participated in the 
MDA than those who did not know about the disease.  There was also no relationship between 
those who knew someone in their household or village disease symptoms and MDA compliance. 
Studies in both Haiti and Indonesia have suggested that knowledge of LF and symptoms, 
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especially if seen in the community through photographs were predictors of compliance with the 
MDA (Mathieu, Lammie et al. 2004; Krentel, Fischer et al. 2006)It is important to achieve high 
levels of coverage in order to interrupt transmission and elimination of diseases targeted by the 
MDA. People who do not participate in the MDA could provide a reservoir for the parasites and 
maintain transmission after the MDA programs are no longer in place. Although coverage was 
high despite low knowledge, for long term sustainability of reduced morbidity and mortality 
from NTDS, people in endemic areas need to be aware of ways to prevent re-infection with the 
diseases that have been reduced through the MDA.  For instance, in Haiti those who knew that 
lymphatic filariasis was transmitted by mosquitoes were more likely to participate in the 
MDA(Mathieu, Lammie et al. 2004). Educational programs as part of MDA have demonstrated 
to increase knowledge of persons and make them aware that avoiding mosquito bites is a way to 
prevent LF (Krentel, Fischer et al. 2006). 
5. Conclusion 
This study stresses the importance of completing a KAP survey in addition to a coverage survey. 
Through evaluation of the MDA program we can identify opportunities for improvement of drug 
delivery and communication strategies to increase awareness of the diseases and the purpose of 
the MDA. Populations living in endemic areas need to be targeted with appropriate health 
education messages and appropriate drug delivery strategies. In the American Samoa, a KAP 
survey identified barriers in MDA participation for LF including not knowing about the MDA, 
and unperceived risk from LF (King, Zielinski-Gutierrez et al. 2011). After educational messages 
were targeted to fill in the knowledge gaps, MDA compliance increased from 71% in 2003 to 
92.7% in 2004 (King, Zielinski-Gutierrez et al. 2011).  
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In the Koza district, those who had knowledge of the disease or knew someone with the disease 
were not more likely to participate in the MDA. One possible way to increase coverage could be 
to increase health education. In Uganda it has been reported that  when health education was 
poor, the information about  appropriate health behaviors to prevent NTD transmission was 
confusing (Parker and Allen 2011). In India, more targeted health messages significantly 
increased MDA awareness and coverage(Babu and Kar 2004). Another way to increase coverage 
would be to increase the number of MDA campaigns per year since the largest barrier to non-
compliance was not being home at the time of the MDA.   
Despite the limitations of the coverage and KAP surveys, they are important tools for 
assessing treatment coverage and barriers to compliance.  Community driven interventions have 
been demonstrated to be very successful and have the potential to significantly reduce the 
morbidity of LF, schistosomiasis, STH, and ochocerciasis.  Evaluating the program can provide 
opportunities to modify the MDA program and increase MDA coverage in the Koza district and 
other districts in Cameroon.   
III. Conclusion 
 
Coverage surveys are an integral part of program evaluation for preventative chemotherapy. 
Coverage surveys evaluate the reported coverage determined by drug distributors during the 
MDA. Without the coverage surveys the program managers would not know how effective their 
efforts are.  By completing this coverage survey in the Koza district, program managers know 
that they can rely on the reported coverage. Although there were slight differences between the 
reported coverage and survey coverage, the results were similar. By knowing that the reported 
coverage is reliable, it can save time and effort needed to complete a coverage survey.  
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Drug coverage is reported for each individual district for program managers, but is also 
reported to the WHO for the entire country. Evaluating coverage for each district on a smaller 
scale is a better way for overall program evaluation. The coverage for Ivermectin/Albendazole 
was close to the target established by WHO, over 70% for the Koza district. However , when 
compared to the coverage for the entire country, Ivermectin/Albendazole coverage is reported to 
be less than 50%.  According to the World Health Organization preventative chemotherapy 
index, the national coverage in 2011 in Cameroon for Ivermectin/Albendazole for treatment of 
STH was 46.07%, praziquantel coverage for schistosomiasis 17.19%, and 
Ivermectin/Albendazole coverage for LF to be 47.6%(WHO 2012).  The coverage for 
Ivermectin/Albendazole for STH, and LF was higher in the Koza district, with 70% coverage and 
praziquantel coverage was also reported higher in the Koza district at 65% for school age 
children.  By looking at the MDA program coverage for the entire country, it would appear that 
the program is not working equally across the country. By administering the KAP survey, 
program evaluators can identify ways to improve the MDA program in a particular area. If the 
MDA coverage is high in one district, but low in another program evaluators can look at the 
results from the survey to find out what is working and what is not working.   
There is a clear association between the burden of NTDs on health and poverty 
(Montresor, Gabrielli et al. 2012).  Receiving deworming drugs can make a huge difference in 
the life of a child as it can impact anemia, improve cognitive and physical development  and 
school attendance for school age children (Crompton and WHO 2006; Hotez, Molyneux et al. 
2006).  Mass drug administration of azithromycin has also been associated with reduced risk of 
childhood diarrhea and respiratory infections in children (Coles, Seidman et al. 2011; Coles, 
Levens et al. 2012).  
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The control of NTDs not only positively impacts the health of the targeted populations 
but also has other implications.  Control of NTDs provides an opportunity to strengthen health 
systems at the same time(WHO 2010). Implementation of preventative chemotherapy helps to 
train a health care workforce for drug distribution and increases health education(WHO 2010).  
These effects on the health care system and capacity building have long term impacts for the 
future in often resource poor countries that are endemic for NTDs.  
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IV. Tables and Figures for Manuscript 
Table 1: Demographics for coverage and KAP surveys. 
 
Survey Demographics  
 
Total N % Female 
(N) 
Median Age Age Range 
Coverage 
Survey 
N=1303 
52% 
(N=673) 
15 years 0-110 years 
KAP survey N=149 62% (N=96) 41 years 14-100 years 
 
 
 
 
 
 
 
Table 2: Relationship between coverage and school attendance for children ages 5-14 years 
 Coverage for Children who attended school (ages 5-
14) 
 Ivermectin/Albendazole Zithromax Praziquantel 
Attended school 92.4 % 89.8% 65.3 % 
Did not attend school 79.9 % 83.3 % 0.69 % 
Odds Ratio 3.1 1.8 269.3 
95% CI 1.7-5.6 1.0-3.1 37.0-1962.4 
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Table 3: Knowledge about NTDs from KAP survey questionnaire 
Table KAP Results % of Respondents N (number of respondents) 
Knowledge of LF: 
  Heard of LF 44.30% N=66 
Symptoms of LF(knew at least 1 symptom) 31.80% N=21 
Transmission of LF 4.50% N=3 
Treatment of LF 23% N=15 
   Knowledge of STH: 
  heard of STH 84.50% N=126 
Transmission of STH 38% N=48 
Treatment of STH 52.30% N=78 
   Knowledge of Schistosomiasis: 
  Heard of Schisto 73% N=109 
Treatment of Schisto 40% N=44 
   Knowledge of Trachoma: 
  Heard of Trachoma 68.50% N=98 
Treatment of Trachoma 30% N=29 
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Table 4: Knowledge of persons with symptoms of NTDs 
 % of Respondents 
Knew someone with symptom Household Village 
Elephantiasis 6.7 % 13.4% 
Hydrocele 7.4 % 27.5% 
Bloody Urine 11.4% 8% 
Blindness 12% 54.4% 
Flies near eyes of children 24.8% 30.9% 
 
 
 
Figure 1: Coverage for self- reporting and reporting for others 
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Appendix 1: Coverage Questionnaire 
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Appendix 2: KAP questionnaire 
Questionnaire 
 
Enquêteurs  |__|__|    Village____________________             Numéro du ménage |__|__|  
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Age    |__|__|        Sexe    M          F 
 
Section 1 
  
1. Est-ce que vous avez entendu parler de éléphantiasis? 
    
1 Oui 
2 Non   
8 Ne sais pas        
9 Refuse de répondre              
 
2. Comment se manifeste éléphantiasis? Encerclez TOUTE(s) réponse(s)    
1. Eléphantiasis 
2. Hydrocèle  
3. Autre    
7.  (précisez) 
8. Ne sais pas 
9. Refuse de répondre 
 
3. Comment est-ce qu’on peut attraper éléphantiasis? Encerclez TOUTE(s) réponse(s  
1. Moustiques 
2. Hériter de mes parents / ma famille  
3. Mal esprits / le sorcier  
7. Autre _________ (précisez) 
8. Ne sais pas 
9. Refuse de répondre  
 
4.   Comment est-ce qu’on peut prévenir ou traiter l’éléphantiasis? Encerclez TOUTE(s) réponse(s)  
   
1. Prendre des médicaments 
2. Dormir sous une moustiquaire 
3. Aller a l’hôpital 
4. Nettoyer les alentours de la maison 
5. Chirurgie 
6. Traitement indigène 
Allez à Section 2 
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7. Autre  _________ (précisez) 
8. Ne sais pas 
9. Refuse de répondre 
Section 2 
  
5…Est-ce que vous avez entendu parler des infections par les vers intestinaux?   
 
1. Oui      
2. Non    
8. Ne sais pas        
9. Refuse de répondre              
 
6…Comment est-ce qu’on peut attraper des infections de vers intestinaux?Encerclez TOUTE(s) 
réponse(s) 
    
0. Manque d’hygiène 
1. Nourriture (pas bien lavée/préparé) 
2. Mouches ou bestioles 
3. Vers à travers la peau de pied  
4. L’eau sale  
5. Ne pas laver les mains 
6. Ne pas utiliser les latrines 
7. Autre   ______________________________ (précisez) 
8. Ne sais pas  
9. Refuse de répondre 
 
7…Comment est-ce qu’on peut prévenir ou traiter les infections de vers intestinaux? Encerclez 
TOUTE(s) réponse(s) 
  
1. Prendre médicaments 
2. Laver les mains 
3. Utiliser les latrines 
4. Bien préparer/laver la nourriture 
5. Porter les chaussures  
Allez à Section 3 
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6. Traitement indigène 
7. Autre  _______(précisez) 
8. Ne sais pas 
9. Refuse de répondre 
 
 
 
 
 
 
 
 
 
 
 
Section 3 
  
8…Est-ce que vous avez entendu parlez de {mot local} schistosomiase? 
1. Oui    8.a. Comment on peut prévenir/traiter schistosomiase?     
   Encerclez TOUTE(s) réponse(s)  
1. Prendre médicaments 
2. Eviter nager l’eau 
3. Utiliser les latrines 
7. Autre        ______________ (précisez) 
8. Ne sais pas 
9. Refuse de répondre 
2. Non    
8. Ne sais pas 
9. Refuse de répondre 
 
9…Est-ce que vous avez entendu parlez de trachome?     
 
1. Oui   9.a.Comment on peut prévenir/traiter le trachome? Encerclez TOUTE(s) 
réponse(s) 
 
1. Laver le visage   
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2. Prendre les médicaments  
3. Utiliser les latrines 
4. Traitement indigène 
7. Autre    __________ 
8. Ne sais pas  
9. Refuse de répondre 
  
2. Non    
8. Ne sais pas 
9. Refuse de répondre 
    
10.  La morbidité 
 
 
Est-ce qu’il y a quelqu’un  
dans votre ménage qui souffre de :  
Vous connaissez quelqu’un  
 dans le village qui souffre de : 
Eléphantiasis Oui   Non                   ? Oui     Non                   ? 
Hydrocèle Oui   Non                   ? Oui     Non                   ? 
Urine sanglante Oui   Non                   ? Oui    Non                   ? 
Aveugle Oui   Non                   ? Oui   Non                   ? 
Mouche au tour des yeux des  
enfants 
Oui   Non                   ? Oui   Non                   ? 
 
 
11. Est-ce que vous avez pris les médicaments chaque fois ils étaient offerts pendant la dernière 
campagne?   
 
1. Oui 
2.  
3. Non 11.a Pour quoi vous n’avez pas pris les médicaments ? Encerclez TOUTE(s) 
réponse(s) 
      
1. Distributeur/infirmier me disait que je ne pouvais pas les prendre  
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2. J’étais enceinte 
3. Je n’étais pas à la maison 
4. J’étais malade  
5. Je ne voulais pas  
6. J’ai peur des symptômes secondaires 
7. Autre __(précisez) 
8. Ne sais pas 
9. Refuse de répondre 
8. Ne sais pas 
9. Refuse de répondre  
  
 
12.  Vous avez eu des problèmes/effets secondaire après avoir pris les médicaments?  
  
1. Oui   12.Après quel médicament cerclez toute(s) réponse(s)     
1. Mectizan/albendazole (oncho/filariose lymphatique)   
2. Zithromax (pour le trachome)    
 
  Quel était le problème? cerclez toute(s) réponse(s)    
                          
0. Mal à la tête       
1. Fièvre  
2. Vertiges 
3. Nausee        
4. Douleur testiculaire 
5. Démangeaison           
6. Douleur générale 
10. Diarria 
11. Vomissement 
12. fatiguee 
7. Autres  _____________________  (précisez)     
8. Ne sais pas 
9. Refuse de répondre  
 
2. Non 
8. Ne sais pas 
9. Refuse de répondre 
 
Si non, allez à 
Section 4 
Allez à Section 4  
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13.  Est-ce que vous avez du payer pour avoir les médicaments ?   
 
1. Oui  13.a.Combien ? _______  
2. Non 
8. Ne sais pas 
9. Refuse de répondre 
 
Section 4 
 
14.  Quel est la source de l’eau pour votre ménage?    
1.   Puits  
 2.  Forage 
2. Source       
3. Rivière (mayo) 
4. Eau vendue dans les bidons 
5. Robinet 
6. L’eau de pluie 
            7.  Autre   __________________________ (précisez) 
            8.  Ne sais pas 
            9.  Refuse de répondre 
  
 
15 Combien de temps devez-vous marcher pour aller chercher de l’eau pendant la saison 
seche 
  : |__|__|__| (minutes)   
  
16.  Où est ce que les membres de vote famille vont faire les selles  de l’habitude?  
1. Champ    
2. Latrine 
3. Rivière    
7.   Autre   ________________________ (précisez) 
8.   Ne sais pas 
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9.  Refuse de répondre 
